Human models as tools in the development of psychotropic drugs

Dialogues in Clinical Neuroscience

Volumn 4, Issue 4, 2002, Pages 377-387

  Gilles, Christian ^a   Schunck, Therese ^a   Erb, Gilles ^a   Namer, Izzie Jacques ^a   Hodé, Yann ^a   Nedelec, Jean François ^a   Boeijinga, Peter ^a   Luthringer, Remy ^a   Macher, Jean Paul ^a  

^a FORENAP   (France)

Author keywords

Alzheimer's disease; Anxiety; Depression; Drug development; Healthy volunteer; Model; Proof of concept; Schizophrenia

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 4 AMINOBUTYRIC ACID RECEPTOR; APOMORPHINE; ATRIAL NATRIURETIC FACTOR; BENZODIAZEPINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DOMPERIDONE; HALOPERIDOL; KETAMINE; LORAZEPAM; NEUROLEPTIC AGENT; NOOTROPIC AGENT; OLANZAPINE; PHYSOSTIGMINE; PSYCHOTROPIC AGENT; SCOPOLAMINE; TETRAGASTRIN; TRYPTOPHAN; VIGABATRIN;

ALZHEIMER DISEASE; ANXIETY DISORDER; AVERSIVE BEHAVIOR; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONDITIONING; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; FINANCE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; MALE; MAXIMUM TOLERATED DOSE; MENTAL DISEASE; MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PANIC; PATIENT COMPLIANCE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROOF OF CONCEPT; PROVOCATION TEST; PSYCHOPHARMACOLOGY; RELIABILITY; SAMPLE SIZE; SCHIZOPHRENIA; TECHNIQUE; TREATMENT INDICATION; VALIDATION PROCESS; VOLUNTEER;

EID: 0037655086     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (114)

1. Food and Drug Administration. www.fda.gov/cder/handbook/phase1.htm. FDA: Rockville, Md. Accessed 30 January 2003.
2. Rapeport G. Proof of concept in big pharma and the biotechnology industry. 6th EUFEPS Conference, Basel, Switzerland, November 30 to December 2, 1999.
3. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development - a critical appraisal. Br J Pharmacol. 1997;44:219-225.
4. d'Ardhuy XL, Boeijinga P, Renault B, et al. Effects of serotonin-selective and classical antidepressants on the auditory P300 cognitive potential. Neuropsychobiology. 1999;40:207-213.
5. Luthringer R, Dago KT, Patat A, et al. Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects. Neuropsychobiology. 1996;34:98-105.
6. Boeijinga P, Muzet M, Gamand S, d'Aniello F, Luthringer R, Macher JP. Double-blind, randomized, placebo-controlled study of the effects on wake EEG of 2 doses of Praxilene® using a cross-over design in elderly healthy male volunteers. Eur Neuropsychopharmacol. 2001;10(suppl 3):S363.
7. Staner L, Luthringer R, Macher JP. The effects of antidepressant drugs on sleep EEG in major depression: mechanisms and therapeutic implications. CNS Drugs. 1999;11:49-60.
8. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull. 1996;32:637-646.
9. Bolo N, Nedelec JF, Muzet M, et al. Central effects of acamprosate. Part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatry Res. 1998;82:115-127.
10. Bolo N, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology. 2000;23:428-438.
11. D'Souza DC, Berman RM, Krystal JH, Charney DS. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biol Psychiatry. 1999;46:1060-1080.
12. Gilles C, Ertlé S. Pharmacological models in Alzheimer's disease research. Dialogues Clin Neurosci. 2000;2:247-255.
13. Ebert U, Kirch W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest. 1998;28:944-949.
14. Richardson JS, Miller PS, Lemay JS, et al. Mental dysfunction and the blockade of muscarinic receptors in the brain of the normal elderly. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:651-654.
15. Sunderland T, Tariot P, Murphy DL, Weingartner H, Mueller EA, Cohen RM. Scopolamine challenges in Alzheimer's disease. Psychopharmacology. 1985;87:247-249.
16. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA III, Murphy DL. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry. 1987;44:418-426.
17. Zemishlany Z, Thorne AE. Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects. Isr J Psychiatry Relat Sci. 1991;28:32-41.
18. Flicker C, Ferris SH, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology. 1992;107:437-441.
19. Gitelman DR, Prohovnik I. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging. 1992;13:313-318.
20. Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang XH, Buccafusco JJ. Central cholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol. 1992;5:72-77.
21. Molchan 5E, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev. 1992;17:215-226.
22. Rabey JM, Neufeld MY, Treves TA, Sifris P, Korczyn AD. Cognitive effects of scopolamine in dementia. J Neural Transm Gen Sect. 1996;103:873-881.
23. Tariot PN, Patel SV, Henderson RE. Age-related decline in central cholinergic function demonstrated with scopolamine. Psychopharmacology. 1996;125:50-56.
24. Ghoneim MM, Mewaldt SP. Studies on human memory: the interactions of diazepam, scopolamine and physostigmine. Psychopharmacology. 1977;52:1-6.
25. Anisman H. Time-dependent changes in activity, reactivity, and responsivity during shock: effects of cholinergic and catecholaminergic manipulations. Neurology. 1977;27:783-790.
26. Liljequist R, Mattila MJ. Effect of physostigmine and scopolamine on the memory functions of chess players. Med Biol. 1979;57:42-405.
27. Mewaldt SP, Ghoneim MM. The effects and interactions of scopolamine and methamphetamine on human memory. Pharmacol Biochem Behav. 1979;10:205-210.
28. Preston GC, Ward C, Lines CR, Poppleton P, Haigh JR, Traub M. Scopolamine and benzodiazepine models of dementia: cross reversals by RO 15-1788 and physostigmine. Psychopharmacology. 1989;98:487-494.
29. Wesnes K, Simpson PM, Kidd AG. The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 997) in man. Med Sci Res. 1987;15:1063-1064.
30. Wesnes KA, Simpson PM, Christmas L, Anand R, McClelland GR. The effects of moclobemide on cognition. J Neural Transm Suppl. 1989;28:91-102.
31. Wesnes K, Anand R, Lorscheid T. Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiatr Scand Suppl. 1990;360:71-72.
32. Wesnes K, Anand R, Simpson P, Christmas L. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. Int J Geriatr Psychiatry. 1990;6:95-102.
33. Wesnes KA, Simpson PM, White L, et al. Cholinesterase inhibition in the scopolamine model of dementia. Ann N Y Acad Sci. 1991;640:268-271.
34. Mohs RC, Davis KL. Interaction of choline and scopolamine in human memory. Life Sci. 1985;37:193-197.
35. Patat A, Klein MJ, Surjus A, Hucher M, Granier J. RU 41656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers. Eur J Clin Pharmacol. 1991;41:225-231.
36. Canal N, Franceschi M, Alberoni M, Castiglioni C, De Moliner P, Longoni A. Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine. Int J Clin Pharmacol Ther Toxicol. 1991;29:103-107.
37. Preda L, Alberoni M, Bressi S, et al. Effects of acute doses of oxiracetam in the scopolamine model of human amnesia. Psychopharmacology. 1993;110:421-426.
38. Jones RW, Wesnes KA, Kirby J. Effects of NMDA modulation in scopolamine dementia. Ann N Y Acad Sci. 1991;640:241-244.
39. Brass EP, Polinsky R, Sramek JJ, et al. Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans. J Clin Psychopharmacol. 1995;15:58-62.
40. Duka T, Ott H, Rohloff A, Voet B. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacology. 1996;123:361-373.
41. Molchan SE, Mellow AM, Lawlor BA, et al. TRH attenuates scopolamineinduced memory impairment in humans. Psychopharmacology. 1990;100:84-89.
42. Lister RG. The amnestic action of benzodiazepines in man. Neurosci. Biobehav Rev. 1985;9:87-94.
43. Curran HV, Schiwy W, Lader M. Differential amnesic properties of benzodiazepines: a dose-response comparison of two drugs with similar elimination half-lives. Psychopharmacology. 1987;92:358-364.
44. Curran HV. Benzodiazepines, memory and mood: a review. Psychopharmacology. 1991;105:1-8.
45. Roehrs T, Zorick F, Sicklesteel L, Wittig R, Hartse K, Roth T. Effects of hypnotics on memory. J Clin Psychopharmacol. 1983;3:310-313.
46. Curran HV, Pooviboonsuk P, Dalton JA, Lader MH. Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine. Psychopharmacology. 1998;135:27-36.
47. Preston GC, Broks P, Traub M, Ward C, Poppleton P, Stahl SM. Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology. 1988;95:208-215.
48. Weingartner H. Models of memory dysfunctions. Ann N Y Acad Sci. 1985;444:359-369.
49. Curran HV, Schifano F, Lader M. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology. 1991;103:83-90.
50. Thiel CM, Henson RN, Morris JS, Friston KJ, Dolan RJ. Pharmacological modulation of behavioral and neuronal correlates of repetition priming. J Neurosci. 2001;21:6846-6852.
51. Sperling R, Greve D, Dale A, et al. Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci U S A. 2002;99:455-460.
52. Duka T, Redeman B, Voet B. Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing. Psychopharmacology. 1995;119:315-324.
53. Thiel CM, Henson RN, Dolan RJ. Scopolamine but not lorazepam modulates face repetition priming: a psychopharmacological fMRI study. Neuropsychopharmacology. 2002;27:282-292.
54. Mandema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally active drugs. Clin Pharmacokinet. 1992;23:191-215.
55. Harris JA, Biersner RJ, Edwards D, Bailey LW. Attention, learning, and personality during ketamine emergence: a pilot study. Anesth Analg. 1975;54:169-172.
56. Pandit SK, Kothary SP, Kumar S. Low dose intravenous infusion technique with ketamine. Anesthesia. 1980;35:669-675.
57. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC. Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol. 1985;5:70-77.
58. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992;260:1209-1213.
59. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry. 1994;51:199-214.
60. Krystal JH, Karper LP, Bennet A, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology. 1998;135:213-229.
61. Krystal JH, D'Souza DC, Karper LP, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology. 1999;145:193-204.
62. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;14:301-307.
63. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biol Psychiatry. 1998;43:811-816.
64. Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106-118.
65. Lahti AC, Weiler MA, Michaelidis T, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25:455-467.
66. Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog Brain Res. 1998;116:421-437.
67. Reuter-Lorenz PA. New visions of the aging mind and brain. Trends Cogn Sci. 2002;6:394-400.
68. Furey ML, Pietrini P, Haxby JV, et al. Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory. Proc Natl Acad Sci U S A. 1997;94:6512-6516.
69. Furey ML, Pietrini P, Alexander GE, Schapiro MB, Horwitz B. Cholinergic enhancement improves performance on working memory by modulating the functional activity in dinstinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans. Brain Res Bull. 2000;51:213-218.
70. Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science. 2000;290:2315-2319.
71. Bradwejn J, de Montigny C. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature. 1984;312:363-364.
72. Rehfeld JF. Cholecystokinin and anxiety, an overview. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL eds. Multiple Cholecystokinin Receptors in CNS. New York, NY: Oxford University Press; 1992:117-120.
73. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry. 1989;46:511-517.
74. Koszycki D, Bradwejn J, Bourin M. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in healthy volunteers. Eur Neuropsychopharmacol. 1991;1:137-414.
75. Koszycki D, Cox BJ, Bradwejn J. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry. 1993;150:1881-1883.
76. Koszycki D, Zacharko RM, Le Medello JM, Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety. 1998;8:1-7.
77. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Am J Psychiatry. 1991;151:603-610.
78. Bradwejn J, Koszycki D, Bourin M. Dose-ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatr Neurosci. 1991;16:91-95.
79. Bradwejn J, Koszycki D, Couëtoux du Tertre A, paradis M, Bourin M. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology. 1994;114:257-261.
80. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry. 1995;38:742-746.
81. Bradwejn J, LeGrand JM, Koszycki D, Bates JHT, Bourin M. Effects of cholecystokinin tetrapeptide on respiratory functions in healthy volunteers. Am J Psychiatry. 1998;155:280-282.
82. Schruers K, Caycedo N, Overbeek T, Büchold H, Bourin M, Griez E. Effects of low dose cholecystokinin on respiratory function in healthy volunteers. Eur Neuropsychopharmacol. 2000;10:419-421.
83. Shlik J, Vasar V, Aluoja A, et al. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry. 1997;42:206-212.
84. Shlik J, Zhou Y, Koszycki D, Vaccarino F, Bradwejn J. Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. J Psychopharmacol. 1999;13:385-390.
85. Jerabek I, Boulenger JP, Bradwejn J, Lavallée YJ, Jolicoeur FB. CCK4-induced panic in healthy subjects I. Psychological and cardiovascular effects. Eur Neuropsychopharmacol. 1999;9:149-155.
86. Flint AJ, Koszycki D, Vaccarino FJ, Cadieux A, Boulenger JP, Bradwejn J. Effect of aging on cholecystokinin-induced panic. Am J Psychiatry. 1998;155:283-285.
87. Le Mellédo JM, Bradwejn J, Koszycki D, Bichet DG, Bellavance F. The role of the α-noradrenergic system in chlolecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiatry. 1998;44:364-366.
88. 3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology. 1999;20:177-187.
89. Wiedemann K, Jahn H, Yassouridis A, Kellner M. Anxiolytic-like effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks. Preliminary findings. Arch Gen Psychiatry. 2001;58:371-377.
90. Kellner M, Yassouridis A, Hua Y, Wendrich M, Jahn H, Wiedemann K. Intravenous C-type natriuretic peptide augments behavioral and endocrine effects of cholecystokinin tetrapeptide in healthy men. J Psychiatr Res. 2002;36:1-6.
91. Zwanzger P, Baghai TC, Schuele C, Ströhle A, Padberg F, Kathmann N. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology. 2001;25:699-703.
92. Benkelfast C, Bradwejn J, Meyer E, et al. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry. 1995;152:1180-1184.
93. Javanmard M, Shlik J, Kennedy SH, Vaccarino FJ, Houle S, Bradwejn J. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry. 1999;45:872-882.
94. LeDoux J. Fear and the brain: where have we been, and where are we going? Biol Psychiatry. 1998;44:1229-1238.
95. Whalen PJ. Fear, vigilance, and ambiguity: initial neuroimaging studies of the human amygdala. Curr Dir Psychol Sci. 1998;7:177-188.
96. Fanselow MS, Le Doux J. Why we think plasticity underlying pavlovian fear conditioning occurs in the basolateral amygdala. Neuron. 1999;23:229-232.
97. Hugdahl K, Berardi A, Thompson WL et al. Brain mechanisms in human classical conditioning: a PET blood flow study. Neuroreport. 1995;6:1723-1728.
98. LaBar KS, Gatenby JC, Gore JC LeDoux JE, Phelps EA. Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron. 1998;20:937-945.
99. Büchel C, Morris J, Dolan RJ, Friston KJ. Brain systems mediating aversive conditioning: an event-related fMRI study. Neuron. 1998;20:947-957.
100. Staner L. Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs. Dialogues Clin Neurosci. 2002;4:342-350.
101. Kahn RS, Davis KL. New development in dopamine and schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1193-1203.
102. Przedborski S, Levivier M, Raftopoulos C, Naini AB, Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effects on dopamine metabolism in humans. Mov Disord. 1995;10:28-36.
103. Luthringer R, Rinaudo G, Toussaint M, et al. Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers. Neuropsychobiology. 1999;39:49-56.
104. McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol. 1990;30:795-803.
105. Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates RA Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br J Clin Pharmacol. 1999;48:323-330.
106. Galderisi S, Mucci A, Bucci P, Mignone ML, Maj M. Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. Psychiatry Res. 1996;67:113-122.
107. Luthringer R. Evaluation de la sphère dopaminergique cérébrale chez l'homme; Mise au point, validation, caractérisation et intérêt du test à l'apomorphine sosu surveillance électroencéphalographique [Doctoral thesis]. Strasbourg, France: Louis Pasteur University; 1998.
108. 11C-raclopride in normal human subjects. Neuropsychopharmacology. 1998;18:18-25.
109. 11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res. 2000;34:35-43.
110. Breier A, Adler CM, Weisenfeld N, et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse. 1998;29:142-147.
111. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000;48:627-640.
112. Lahti AC, Koffel B, Laporte D, et al. Subanesthetic doses of ketamine simulate psychosis in schizophrenia. Neuropsychopharmacology. 1994;13:9-19.
113. Tamminga CA, Medoff DR. Studies in schizophrenia: pathophysiology and treatment. Dialogues Clin Neurosci. 2002;4:000-000.
114. Malhotra AK, Adler CM, Kennison SD, et al. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry. 1997;42:664-668.